Episode 38: New trials you need to know about
In episode 38 we try to go over 8 new studies in one podcast but only get half-way there. We cover 2 inhaled anticholinergic studies, one new glucose lowering trial and the latest smoking cessation RCT. Mike and James wax poetically about a variety of issues and demonstrate clearly their well-honed technique of how not to stay foccussed, succint and to-the-point which explains why we only got to half the studies.
Show Notes
1) Inhaled anticholinergics – for better or worse?
Tiotropium given for 4 years on-top of existing therapy – no increase in mortality and fewer myocardial infarctions
Inhaled anticholinergics increases risk of cardiovascular death – but not total mortality
2) VADT – trial – the third study showing either no benefit or harm from aggressively lowering blood glucose – glycated hemoglobin level reduced from 8.4% to 6.9%
3) Varenicline for smoking cessation Varenicline verus transdermal nicotine
Evidence showing 0.5 mg BID of varenicline is as effective as 1 mg BID
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
